Abeona Therapeutics (PCJ) AI Stock Analysis

Company Guidance

Guidance from the call emphasized that future disclosures will be anchored to completed operational achievements (patients treated in the quarter and net revenue recognized), and management reiterated a near‑term commercial cadence goal of about 1 patient per month per QTC once centers reach steady state; key metrics cited included Q2 net ZEVASKYN revenue of $11.4M (up 31% QoQ from $8.7M), five patients treated in Q2 (revenue recognized for four due to one low‑yield batch), 12 patients treated since launch (5 in Q2 plus 3 in Q3 to date), seven activated QTCs, ~40% of the addressable market with in‑state QTC access, Medicare representing ~10% of payer mix, NTAP granted effective Oct 1, 2026 (FY2027) as 1 of 3 approvals of 15 applicants, commercial manufacturing averaging ~9 sheets per lot (capacity up to 12 sheets) with a <4‑sheet low‑yield threshold that precludes billing, Q2 gross margin ~63% (management targets ~85–90% at full operating capacity), Q2 R&D $5.0M and SG&A $15.8M, net loss $20.2M ($0.35/share) vs $17.1M ($0.30) in Q1, and cash, cash equivalents and short‑term investments of $146.8M as of June 30, 2026.